A practical approach to relapsed multiple myeloma.

Area of Science:

• Hematology
• Oncology
• Clinical Therapeutics

Background:

• Multiple myeloma treatment has significantly improved survival rates over the last decade.
• Despite advances and novel agents, multiple myeloma remains largely incurable, necessitating repeated therapies.
• Current treatment sequencing for relapsed disease is complex and individualized.

Purpose of the Study:

• To provide practical guidance for selecting relapsed multiple myeloma therapies.
• To structure therapeutic decisions using a series of key questions.
• To highlight recent novel agents like carfilzomib and pomalidomide, and emerging treatments.

Main Methods:

• Review of current treatment strategies for relapsed multiple myeloma.
• Emphasis on factors influencing treatment choice, including prior response, risk status, and novel agents.
• Structured decision-making framework based on five critical questions.

Main Results:

• Identification of key factors for guiding relapsed multiple myeloma therapy selection.
• Highlighting the roles of carfilzomib and pomalidomide in current treatment paradigms.
• Inclusion of information on agents currently under development for future therapeutic options.

Conclusions:

• Selecting relapsed multiple myeloma therapy requires careful consideration of multiple patient-specific and disease-related factors.
• Novel agents and a structured approach can optimize treatment selection for improved outcomes.
• Ongoing research and development promise further advancements in managing relapsed multiple myeloma.